Effect of two drug Eperisone and Tolperisone on patients of Acute Low Back pai

Phase 4

• Conditions: Health Condition 1: null- Acute Low Back Pain

• Registration Number: CTRI/2016/12/007548
• Lead Sponsor: Department of Pharmacology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

I.Age: age limit between 18 to 55 years.

II.Duration of pain: less than 4 weeks.

III.Radiological: spondylosis deformanace, prolapsed intervertebral disc.

IV.Muscular spasm: acute muscular spasm in lower back muscles.

V.Pain exacerbated by hyperextension and alleviated by flexion.

VI.Patient who gives written informed consent

Exclusion Criteria

I.Patients with a history of sensitivity to any of the drugs.

II.Patients with fracture or injury to spine

III.Patients with pain more than 4weeks.

IV.Patient with history of spondylitis/severe arthritis/T.B. spine / cancer / osteoporosis.

V.Patients with history of taking centrally acting muscle relaxant within 7 days.

VI.Muscular diseases: myositis, poliomyositis, muscular dystrophia and myotonia.

VII.Congenital spinal deformity.

VIII.Pregnant or lactating women.

IX.Patients with tuberculosis, diabetes, acute renal disease, or liver disease.

X.Patients who were unable to continue for the proposed length of treatment or return for follow-up visits.

XI.Do not give consent.

XII.Patients with lumbar pathologies diagnosed by radiology such as lumbar herniated disc disease, spondylolisthesis, narrow spinal canal, scoliosis or other spinal deformities, fracture, mass lesions

XIII.Patients with a history of previous lumbar surgery.

XIV.Patients with polyneuropathy or mononeuropathy.

XV.Patients with a neoplastic disease.

XVI.Patients with a psychiatric disease.

XVII.Patients have a sciatica, radiculopathy, neurological deficits.

XVIII.Patients with an epileptic or severe neurological disease

XIX.Calcium metabolism disease, Vitamin D deficiency, Osteoporosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To find effectiveness of Tolperisone and Eperisone in acute low back painTimepoint: For 7 days

Secondary Outcome Measures

Name	Time	Method
2)To find effectiveness of central muscle relaxant in acute low back pain. <br/ ><br>3)To find how much improvement in patients of acute low back pain after treatment <br/ ><br>Timepoint: for 7 days